Insider Selling: DexCom, Inc. (NASDAQ:DXCM) Director Sells 2,750 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director now directly owns 56,621 shares in the company, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

DexCom Price Performance

Shares of NASDAQ DXCM traded down $1.01 during mid-day trading on Friday, reaching $80.00. 5,238,495 shares of the company traded hands, compared to its average volume of 4,356,495. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The firm has a market cap of $31.37 billion, a PE ratio of 59.70, a price-to-earnings-growth ratio of 1.71 and a beta of 1.46. The stock has a fifty day simple moving average of $80.08 and a 200-day simple moving average of $79.39.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 earnings per share. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Institutional investors and hedge funds have recently bought and sold shares of the business. Private Trust Co. NA grew its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of DexCom during the 1st quarter valued at $27,000. Optiver Holding B.V. purchased a new position in shares of DexCom during the 4th quarter valued at $33,000. Finally, TD Private Client Wealth LLC grew its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. Canaccord Genuity Group boosted their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Piper Sandler reduced their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Mizuho began coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Finally, Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.